EFS among variably defined groups of good-prognosis patients. NCI SR patients with favorable genetic features who were MRD⁻ at both day 8 and day 29 were the best group, with a 97% plus or minus 1% 5-year EFS. They had statistically better outcomes than either patients without the genetic features who had the same MRD characteristics (92% ± 3%; P = .020) or end-induction MRD⁻, favorable genetic patients who were day-8 MRD⁺ (93% ± 2%; P = .024).